Evidence map›Paper›PMID 34183225›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2021

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey.

Vincenzo Di Noia, Davide Renna, Vittoria Barberi, Mattia Di Civita, Federica Riva, Giulia Costantini, Emanuela Dell' Aquila, Michelangelo Russillo, Domenico Bracco, Antonia Marina La Malfa and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Drivers and barriers to COVID-19 vaccination in Australians with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  11. Vaccine hesitancy in cancer patients: A rapid review.Patient education and counseling · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Vincenzo Di NoiaMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincenzo.dinoia@ifo.gov.it.
Davide RennaMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: renna.davide@ifo.gov.it.
Vittoria BarberiDipartimento di Medicina Clinica e Molecolare, Università La Sapienza di Roma, Rome, Italy. Electronic address: vittoria.barberi@ifo.gov.it.
Mattia Di CivitaDipartimento di Medicina Clinica e Molecolare, Università La Sapienza di Roma, Rome, Italy. Electronic address: mattia.dicivita@ifo.gov.it.
Federica RivaDipartimento di Medicina Clinica e Molecolare, Università La Sapienza di Roma, Rome, Italy. Electronic address: federica.riva@ifo.gov.it.
Giulia CostantiniMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: giulia.costantini@ifo.gov.it.
Emanuela Dell' AquilaMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: emanuela.dellaquila@ifo.gov.it.
Michelangelo RussilloMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: michelangelo.russillo@ifo.gov.it.
Domenico BraccoMedical Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: domenico.bracco@ifo.gov.it.
Antonia Marina La MalfaHospital Pharmacy, Regina Elena National Cancer Institute, Rome, Italy. Electronic address: antonia.lamalfa@ifo.gov.it.
Diana GiannarelliBiostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: diana.giannarelli@ifo.gov.it.
Francesco CognettiMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Dipartimento di Medicina Clinica e Molecolare, Università La Sapienza di Roma, Rome, Italy. Electronic address: francesco.cognetti@ifo.gov.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with cancer have an increased risk of complications from coronavirus disease 2019 (COVID-19) infection, including death, and thus, they were considered as high-priority subjects for COVID-19 vaccination. We report on the compliance with the COVID-19 vaccine of patients affected by solid tumours. MATERIALS AND

methodsPatients with cancer afferent to Medical Oncology 1 Unit of Regina Elena National Cancer Institute in Rome were considered eligible for vaccination if they were receiving systemic immunosuppressive antitumor treatment or received it in the last 6 months or having an uncontrolled advanced disease. The Pfizer BNT162b2 vaccine was proposed to all candidates via phone or during a scheduled visit. The reasons for refusal were collected by administrating a 6-item multiple-choice questionnaire.

resultsFrom 1st March to 20th March 2021, of 914 eligible patients, 102 refused vaccination (11.2%, 95% confidence interval [CI] 9.1-13.2). The most frequent (>10%) reasons reported were concerns about vaccine-related adverse events (48.1%), negative interaction with concomitant antitumor therapy (26.7%), and the fear of allergic reaction (10.7%). The refusal rate (RR) after 15th March (date of AstraZeneca-AZD1222 suspension) was more than doubled compared with the RR observed before (19.7% versus 8.6%, odds ratio [OR] 2.60, 95% CI 1.69-3.99; P < 0.0001). ECOG-PS 2 was associated with higher RR compared with ECOG-PS 0-1 (OR 2.94, 95% CI 1.04-8.34; P = 0.04). No statistically significant differences in RR according to other clinical characteristics were found.

conclusionsOur experience represents the first worldwide report on the adherence of patients with cancer to COVID-19 vaccination and underlines how regulatory decisions and media news spreading could influence the success of the campaign.

Indexed as

AdultAgedAged, 80 and overBNT162 VaccineChAdOx1 nCoV-19COVID-19COVID-19 VaccinesFemaleHumansItalyMaleMiddle AgedNeoplasmsSARS-CoV-2Surveys and QuestionnairesVaccinationBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesBNT162b2Cancer patientsCOVID-19Public healthRefusalSARS-CoV-2Vaccine

Identifiers

PMID34183225
PMCPMC8149194
OpenAlexW3164652662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.